Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
1,569
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Anna M. Tanasijevica Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Anna Revettea Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Heidi D. Klepinb Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USAView further author information
,
Amer Zeidanc Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USAView further author information
,
Danielle Townsleyd Oncology at MedImmune/AstraZeneca, Gaithersburg, MD, USAView further author information
,
Courtney D. DiNardoe Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Marie Sebertf Service de Hematologie Seniors, Hospital Saint Louis, Universit Paris 7, Paris, FranceView further author information
,
Amy E. DeZerng Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USAView further author information
,
Richard M. Stoneh Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Emily S. Magnavitaa Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Richard Chena Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Mikkael A. Sekeresi Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USAView further author information
&
Gregory A. Abela Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA;h Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 2900-2904 | Received 11 May 2020, Accepted 29 Jun 2020, Published online: 15 Jul 2020

References

  • Koutsavlis I. Transfusion thresholds, quality of life, and current approaches in myelodysplastic syndromes. Anemia. 2016;2016:8494738.
  • Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91(12):1588–1590.
  • Baron DM, Franchini M, Goobie SM, et al. Patient blood management during the COVID-19 pandemic – a narrative review. Anaesthesia. 2020.
  • Pagano MB, Hess JR, Tsang HC, et al. Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State. Transfusion. 2020;60(5):908–911.
  • Shander A, Goobie SM, Warner MA, et al. The essential role of patient blood management in a pandemic: a call for action. Anesth Analg. 2020;131(1):74–85.
  • Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409–417.
  • Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453–2462.
  • Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559–1567.
  • Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042.
  • Franchini M, Marano G, Mengoli C, et al. Red blood cell transfusion policy: a critical literature review. Blood Transfus. 2017;15(4):307–317.
  • Gu Y, Estcourt LJ, Doree C, et al. Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. Cochrane Database Syst Rev. 2015;10:CD011577.
  • Stanworth SJ, Killick S, McQuilten ZK, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189(2):279–290.
  • Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376–380.
  • Fitch K, Berenstein SJ, Aguilar MD, et al. The RAND/UCLA appropriateness method user's manual. Santa monica (CA): Rand Corporation; 2001.
  • Escaron AL, Chang Weir R, Stanton P, et al. Testing an adapted modified Delphi method: synthesizing multiple stakeholder ratings of health care service effectiveness. Health Promot Pract. 2016;17(2):217–225.
  • Park RE, Fink A, Brook RH, et al. Physician ratings of appropriate indications for six medical and surgical procedures. Am J Public Health. 1986;76(7):766–772.
  • van Vliet DC, van der Meij E, Bouwsma EV, et al. A modified Delphi method toward multidisciplinary consensus on functional convalescence recommendations after abdominal surgery. Surg Endosc. 2016;30(12):5583–5595.
  • Solle JC, Steinberg A, Marathe P, et al. Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55(1):242–244.
  • Button E, Gavin NC, Chan RJ, et al. Harnessing the power of clinician judgement. Identifying risk of deteriorating and dying in people with a haematological malignancy: a Delphi study. J Adv Nurs. 2019;75(1):161–174.
  • King PK, Fosnight SM, Bishop JR. Consensus clinical decision-making factors driving anticoagulation in atrial fibrillation. Am J Cardiol. 2019;124(7):1038–1043.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.